Aeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”), a specialty biopharmaceutical company engaged in developing and
commercializing novel treatments in oncology, endocrinology and women’s health, today announced the results of the vote on
directors held at its 2016 annual meeting of shareholders held earlier today on May 10, 2016. Each of the director nominees
proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies
with regard to voting on the six directors nominated for election as set forth in the table below:
Name of Nominee |
|
|
Votes For |
|
% |
|
Votes Withheld |
% |
Michael Cardiff |
|
|
1,254,909 |
|
88.53 |
|
162,647 |
11.47 |
David A. Dodd |
|
|
1,187,024 |
|
83.74 |
|
230,532 |
16.26 |
Carolyn Egbert |
|
|
1,268,485 |
|
89.48 |
|
149,071 |
10.52 |
Juergen Ernst |
|
|
1,266,892 |
|
89.37 |
|
150,664 |
10.63 |
Gérard Limoges |
|
|
1,268,600 |
|
89.49 |
|
148,956 |
10.51 |
Ken Newport |
|
|
1,254,215 |
|
88.48 |
|
163,341 |
11.52 |
All other matters at the shareholders' meeting were also approved by shareholders.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for
others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts
is the acquisition or license of products that are relevant to our therapeutic areas of focus. We also intend to license out
certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to
ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and
patients who will benefit from our products. For more information, visit www.aezsinc.com.
Aeterna Zentaris Inc.
Philip A. Theodore
Senior Vice President
843-900-3223
IR@aezsinc.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160510006447/en/